Elevance Health (NYSE:ELV) Issues Earnings Results

Elevance Health (NYSE:ELV) announced its quarterly earnings results on Thursday. The company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.80 by $0.04, Zacks reports. Elevance Health had a return on equity of 19.56% and a net margin of 3.68%. Elevance Health updated its FY 2025 guidance to 34.150-34.850 EPS.

Elevance Health Stock Up 0.8 %

Elevance Health stock traded up $3.19 during trading hours on Thursday, hitting $393.92. The company had a trading volume of 539,696 shares, compared to its average volume of 1,712,752. The firm’s fifty day moving average is $386.32 and its 200-day moving average is $463.64. The firm has a market capitalization of $91.36 billion, a P/E ratio of 14.44, a price-to-earnings-growth ratio of 1.10 and a beta of 0.84. Elevance Health has a fifty-two week low of $362.21 and a fifty-two week high of $567.26. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.50 and a quick ratio of 1.50.

Elevance Health Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 25th. Investors of record on Monday, March 10th will be issued a dividend of $1.71 per share. This is a boost from Elevance Health’s previous quarterly dividend of $1.63. This represents a $6.84 annualized dividend and a dividend yield of 1.74%. Elevance Health’s dividend payout ratio (DPR) is currently 23.77%.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ELV. Raymond James set a $485.00 price target on shares of Elevance Health in a research report on Friday, October 18th. Stephens lowered shares of Elevance Health from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $520.00 to $440.00 in a report on Wednesday. Argus lowered Elevance Health from a “buy” rating to a “hold” rating in a research report on Friday, October 18th. Morgan Stanley decreased their target price on Elevance Health from $643.00 to $551.00 and set an “overweight” rating for the company in a research report on Wednesday, October 23rd. Finally, Mizuho dropped their target price on Elevance Health from $585.00 to $505.00 and set an “outperform” rating on the stock in a report on Tuesday, November 5th. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $524.87.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.